Olpasiran for Atherosclerotic Cardiovascular Disease

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Atherosclerotic Cardiovascular DiseaseOlpasiran - Drug
Eligibility
18 - 85
All Sexes
What conditions do you have?
Select

Study Summary

The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

Eligible Conditions
  • Atherosclerotic Cardiovascular Disease

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 11 Secondary · Reporting Duration: Approximately 4 years

Approximately 4 years
Time to CHD death
Time to CHD death or myocardial infarction, whichever occurs first
Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first
Time to cardiovascular death
Myocardial Infarction
Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first
Time to coronary revascularization
Time to death by any cause
Time to ischemic stroke
Time to myocardial infarction
Time to urgent coronary revascularization
Baseline and Week 48
Lipoproteins

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Olpasiran
1 of 2
Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

6000 Total Participants · 2 Treatment Groups

Primary Treatment: Olpasiran · Has Placebo Group · Phase 3

Olpasiran
Drug
Experimental Group · 1 Intervention: Olpasiran · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Olpasiran
2020
Completed Phase 2
~320

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 4 years

Who is running the clinical trial?

AmgenLead Sponsor
1,296 Previous Clinical Trials
1,322,818 Total Patients Enrolled
MDStudy DirectorAmgen
838 Previous Clinical Trials
891,919 Total Patients Enrolled

Eligibility Criteria

Age 18 - 85 · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a high level of Lp(a) during screening.